Chapter review

Fitzgerald PMHNP board review. ch11. Substance-related Disorders. This is drive 2 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Intoxication Presentation by Class. Topic. Opioid Intoxication Signs. Bottom Line Summary. * **Opioid intoxication** presents with the core clinical triad of **pupillary constriction** (pinpoint pupils or miosis), **respiratory depression** (bradypnea or shallow breathing), and **central nervous system depression** (drowsiness, lethargy, stupor, or coma). * **Dextroamphetamine** and other sympathomimetic stimulant intoxications produce **pupillary dilation** (mydriasis), severe hypertension (such as 180 over 115 mmHg), and marked tachycardia (such as 140 beats per minute), directly contrasting with the **pupillary constriction**, bradycardia, and hypotension seen in **opioid intoxication**. * **Naloxone** (**Narcan**) nasal spray or intravenous administration is the **first-line** emergency treatment for acute **opioid overdose** with respiratory depression to rapidly displace opioids from mu-opioid receptors and restore breathing. * **Naltrexone** is an oral or long-acting injectable (**Vivitrol**) mu-opioid antagonist used for alcohol dependence and opioid relapse prevention, but it is strictly contraindicated in patients currently using opioids or expecting upcoming opioid analgesia (such as scheduled surgical or dental procedures within 30 days) due to blocking pain relief and precipitating severe withdrawal. * **Opioid withdrawal** manifests as multi-system autonomic hyperactivity with muscle cramps, joint aches (arthralgia), diarrhea, rhinorrhea, lacrimation, yawning, and tremor, scored clinically using the **Clinical Opioid Withdrawal Scale** (**COWS**) where scores range from 5 to 12 for mild, 13 to 24 for moderate, 25 to 36 for moderately severe, and greater than 36 for severe withdrawal. * Diagnostic criteria for **substance use disorder** require 2 or more of 11 criteria within a 12-month period, categorized by severity as mild (2 to 3 criteria), moderate (4 to 5 criteria), or severe (6 or more criteria) using the mnemonic **tempted with cocaine, Scotch, and rum**. Opioid Intoxication Signs and Clinical Management. **Opioid intoxication** occurs when exogenous opioid agonists bind central and peripheral mu-opioid receptors, down-regulating central nervous system arousal and autonomic output. Core Clinical Presentation. * **Ocular Findings:** **Pupillary constriction** (pinpoint pupils or miosis) is the hallmark physical finding on board examination. * **Respiratory Findings:** **Respiratory depression** with reduced respiratory rate, hypoventilation, and shallow breathing. * **Neurologic Findings:** Sedation, slurred speech, psychomotor retardation, stupor, and unresponsiveness. * **Autonomic and Gastrointestinal Findings:** Hypotension, bradycardia, hypothermia, decreased bowel sounds, and severe constipation. **First-line** intervention for acute **opioid intoxication** complicated by respiratory depression is immediate administration of **naloxone** (**Narcan**) via intranasal or parenteral routes to restore airway patency and spontaneous ventilation. **Safety alert:** When administering **naloxone**, monitor the patient continuously because the elimination half-life of **naloxone** (30 to 90 minutes) is substantially shorter than that of long-acting opioids like **methadone** or sustained-release **morphine**. Respiratory depression can recur as **naloxone** wears off, requiring repeat dosing. Rapid reversal can also trigger acute precipitated withdrawal with severe agitation, vomiting, and tachycardia. **Board trap:** Do not confuse **naloxone** with **naltrexone**. **Naloxone** is a short-acting emergency antagonist used for acute overdose reversal. **Naltrexone** is a long-acting antagonist used for long-term relapse prevention in alcohol use disorder and opioid use disorder. Administering **naltrexone** to a patient with active opioids in their system or one requiring acute opioid pain control will precipitate immediate, severe withdrawal and completely block required analgesia. Compare and Distinguish. Opioid Intoxication vs. Stimulant Intoxication. * **Think Opioid Intoxication when:** Stem describes pinpoint pupils (**pupillary constriction**), respiratory depression, bradycardia, hypotension, and central nervous system lethargy. * **Think Stimulant Intoxication when:** Stem describes dilated pupils (**pupillary dilation** or mydriasis), severe hypertension (e.g., 180 over 115 mmHg), tachycardia (e.g., 140 beats per minute), muscle weakness, and cardiac hyperarousal. * **Priority difference:** Opioid intoxication requires immediate airway protection and **naloxone** reversal; stimulant intoxication requires cardiovascular monitoring and cooling or sedation for adrenergic crisis. Opioid Intoxication vs. Opioid Withdrawal. * **Think Opioid Intoxication when:** Stem reveals miosis, drowsiness, hypoventilation, decreased bowel sounds, and bradycardia. * **Think Opioid Withdrawal when:** Stem reveals mydriasis, lacrimation, rhinorrhea, yawning, piloerection (gooseflesh), severe abdominal cramping, diarrhea, and joint pain (arthralgia). * **Board distinction:** Intoxication slows all systems down; withdrawal accelerates autonomic output up. Fitzgerald Board Practice Questions. Question 1. A 19-year-old man is brought to the emergency department by his friends who are concerned about his health. Physical examination reveals muscle weakness, dilated pupils, heart rate 140 beats per minute, and blood pressure 180 over 115 mmHg. His friends say he may have taken something orally about two hours ago. Which of the following is the most likely illicit substance? A. Cannabis B. Dextroamphetamine C. Diazepam D. Oxycodone Pause. Answer. **Quick Answer:** **Dextroamphetamine** is the correct option because sympathomimetic stimulants cause marked adrenergic hyperarousal including pupillary dilation, severe hypertension, and tachycardia. **Key Clue:** Dilated pupils, heart rate 140 beats per minute, and blood pressure 180 over 115 mmHg. **Best Answer:** B. Dextroamphetamine **Why It Is Correct:** **Dextroamphetamine** increases synaptic dopamine and norepinephrine, producing acute sympathomimetic toxicity characterized by mydriasis (dilated pupils), extreme hypertension, tachycardia, and muscular agitation. **Why the Other Choices Are Wrong:** * **A:** **Cannabis** intoxication typically presents with conjunctival injection (red eyes), increased appetite, dry mouth, and mild tachycardia, but not severe malignant hypertension or marked pupil dilation. * **C:** **Diazepam** is a benzodiazepine that causes central nervous system depression, ataxia, slurred speech, and respiratory depression rather than sympathetic hyperarousal. * **D:** **Oxycodone** is an opioid agonist that causes **pupillary constriction** (pinpoint pupils), bradycardia, hypotension, and respiratory depression, which is the exact opposite of this patient's presentation. **Test-Taking Pearl:** On board exams, pupil size is the critical pivot point: opioids constrict pupils (miosis), whereas stimulants like **dextroamphetamine** or **cocaine** dilate pupils (mydriasis). Question 2. Dana, a 44-year-old registered nurse, is preparing to be discharged from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help keep her abstinent from alcohol. She has extensive dental work planned to begin within the next month. Which medication would be contraindicated for use given this information? A. Disulfiram B. Naltrexone C. Acamprosate D. Sertraline Pause. Answer. **Quick Answer:** **Naltrexone** is contraindicated because blocking mu-opioid receptors prevents opioid analgesics from working during her upcoming dental procedures. **Key Clue:** Extensive dental work planned within the next month requiring potential opioid analgesia. **Best Answer:** B. Naltrexone **Why It Is Correct:** **Naltrexone** is a mu-opioid receptor antagonist that blocks the euphoric and analgesic effects of opioids. If prescribed to a patient undergoing extensive dental procedures requiring opioid analgesics, **naltrexone** will block pain relief and can precipitate acute opioid withdrawal if opioids are administered. **Why the Other Choices Are Wrong:** * **A:** **Disulfiram** inhibits aldehyde dehydrogenase to cause an aversion reaction with alcohol, but it does not interact with opioid receptors or block dental pain management. * **C:** **Acamprosate** modulates GABA and glutamate neurotransmission to maintain alcohol abstinence and is excreted by the kidneys, making it completely safe for patients requiring opioid analgesics for procedures. * **D:** **Sertraline** is an SSRI antidepressant that does not block opioid analgesia, although it is not a primary FDA-approved craving reduction agent for alcohol abstinence. **Test-Taking Pearl:** Always screen for upcoming surgeries or invasive procedures before initiating **naltrexone** or **Vivitrol**, as opioid blockade prevents standard perioperative pain management. Question 3. Match the substance with the characteristic withdrawal symptoms below: muscle cramps, joint aches (arthralgia), diarrhea, rhinorrhea, lacrimation, and piloerection. A. Amphetamine B. Opioid C. Alcohol D. Cannabis Pause. Answer. **Quick Answer:** **Opioid** withdrawal causes multi-system autonomic rebounding including muscle cramps, joint aches, lacrimation, rhinorrhea, and diarrhea. **Key Clue:** Muscle cramps, joint aches, rhinorrhea, lacrimation, and diarrhea. **Best Answer:** B. Opioid **Why It Is Correct:** **Opioid** withdrawal results from the loss of mu-opioid receptor stimulation, leading to autonomic surge, severe gastrointestinal hypermotility (diarrhea and cramps), flu-like lacrimation and rhinorrhea, and musculoskeletal pain evaluated via the **COWS** scale. **Why the Other Choices Are Wrong:** * **A:** **Amphetamine** withdrawal produces crash symptoms including severe depression, fatigue, vivid dreams, increased appetite, and psychomotor slowing. * **B:** Incorrect choice as this is the correct answer. * **C:** **Alcohol** withdrawal produces central nervous system excitability with hand tremors, sweating, hypertension, tachycardia, confusion, and potential seizures or delirium tremens. * **D:** **Cannabis** withdrawal produces mild restlessness, irritability, insomnia, decreased appetite, and mild abdominal discomfort without severe autonomic collapse. **Test-Taking Pearl:** **COWS** measures opioid withdrawal symptoms, whereas **CIWA-Ar** measures alcohol withdrawal symptoms; memorize which scale applies to which substance. Next Study Step. Review **Fitzgerald Chapter 11 Alcohol Withdrawal Protocols and Pharmacotherapy** to master **CIWA** scoring, benzodiazepine symptom-triggered regimens, and the pharmacology of **acamprosate**, **disulfiram**, and **naltrexone**. * **Why this is the best next step:** It cements the critical exam distinctions between opioid protocols (**COWS** and **naloxone**) and alcohol protocols (**CIWA**, thiamine prior to glucose, and anti-craving agents). * **What knowledge gap it closes:** It eliminates confusion regarding when to select **acamprosate** over **naltrexone** in patients with liver disease versus renal impairment. * **What confusion it helps prevent on boards:** It prevents picking **naloxone** when the question stem is actually asking for alcohol craving reduction or chronic opioid maintenance therapy. Bottom Line Summary. * **Opioid intoxication** presents with the core clinical triad of **pupillary constriction** (pinpoint pupils or miosis), **respiratory depression** (bradypnea or shallow breathing), and **central nervous system depression** (drowsiness, lethargy, stupor, or coma). * **Dextroamphetamine** and other sympathomimetic stimulant intoxications produce **pupillary dilation** (mydriasis), severe hypertension (such as 180 over 115 mmHg), and marked tachycardia (such as 140 beats per minute), directly contrasting with the **pupillary constriction**, bradycardia, and hypotension seen in **opioid intoxication**. * **Naloxone** (**Narcan**) nasal spray or intravenous administration is the **first-line** emergency treatment for acute **opioid overdose** with respiratory depression to rapidly displace opioids from mu-opioid receptors and restore breathing. * **Naltrexone** is an oral or long-acting injectable (**Vivitrol**) mu-opioid antagonist used for alcohol dependence and opioid relapse prevention, but it is strictly contraindicated in patients currently using opioids or expecting upcoming opioid analgesia (such as scheduled surgical or dental procedures within 30 days) due to blocking pain relief and precipitating severe withdrawal. * **Opioid withdrawal** manifests as multi-system autonomic hyperactivity with muscle cramps, joint aches (arthralgia), diarrhea, rhinorrhea, lacrimation, yawning, and tremor, scored clinically using the **Clinical Opioid Withdrawal Scale** (**COWS**) where scores range from 5 to 12 for mild, 13 to 24 for moderate, 25 to 36 for moderately severe, and greater than 36 for severe withdrawal. * Diagnostic criteria for **substance use disorder** require 2 or more of 11 criteria within a 12-month period, categorized by severity as mild (2 to 3 criteria), moderate (4 to 5 criteria), or severe (6 or more criteria) using the mnemonic **tempted with cocaine, Scotch, and rum**. Opioid Intoxication Signs and Clinical Management. **Opioid intoxication** occurs when exogenous opioid agonists bind central and peripheral mu-opioid receptors, down-regulating central nervous system arousal and autonomic output. Core Clinical Presentation. * **Ocular Findings:** **Pupillary constriction** (pinpoint pupils or miosis) is the hallmark physical finding on board examination. * **Respiratory Findings:** **Respiratory depression** with reduced respiratory rate, hypoventilation, and shallow breathing. * **Neurologic Findings:** Sedation, slurred speech, psychomotor retardation, stupor, and unresponsiveness. * **Autonomic and Gastrointestinal Findings:** Hypotension, bradycardia, hypothermia, decreased bowel sounds, and severe constipation. **First-line** intervention for acute **opioid intoxication** complicated by respiratory depression is immediate administration of **naloxone** (**Narcan**) via intranasal or parenteral routes to restore airway patency and spontaneous ventilation. **Safety alert:** When administering **naloxone**, monitor the patient continuously because the elimination half-life of **naloxone** (30 to 90 minutes) is substantially shorter than that of long-acting opioids like **methadone** or sustained-release **morphine**. Respiratory depression can recur as **naloxone** wears off, requiring repeat dosing. Rapid reversal can also trigger acute precipitated withdrawal with severe agitation, vomiting, and tachycardia. **Board trap:** Do not confuse **naloxone** with **naltrexone**. **Naloxone** is a short-acting emergency antagonist used for acute overdose reversal. **Naltrexone** is a long-acting antagonist used for long-term relapse prevention in alcohol use disorder and opioid use disorder. Administering **naltrexone** to a patient with active opioids in their system or one requiring acute opioid pain control will precipitate immediate, severe withdrawal and completely block required analgesia. Compare and Distinguish. Opioid Intoxication vs. Stimulant Intoxication. * **Think Opioid Intoxication when:** Stem describes pinpoint pupils (**pupillary constriction**), respiratory depression, bradycardia, hypotension, and central nervous system lethargy. * **Think Stimulant Intoxication when:** Stem describes dilated pupils (**pupillary dilation** or mydriasis), severe hypertension (e.g., 180 over 115 mmHg), tachycardia (e.g., 140 beats per minute), muscle weakness, and cardiac hyperarousal. * **Priority difference:** Opioid intoxication requires immediate airway protection and **naloxone** reversal; stimulant intoxication requires cardiovascular monitoring and cooling or sedation for adrenergic crisis. Opioid Intoxication vs. Opioid Withdrawal. * **Think Opioid Intoxication when:** Stem reveals miosis, drowsiness, hypoventilation, decreased bowel sounds, and bradycardia. * **Think Opioid Withdrawal when:** Stem reveals mydriasis, lacrimation, rhinorrhea, yawning, piloerection (gooseflesh), severe abdominal cramping, diarrhea, and joint pain (arthralgia). * **Board distinction:** Intoxication slows all systems down; withdrawal accelerates autonomic output up. Fitzgerald Board Practice Questions. Question 1. A 19-year-old man is brought to the emergency department by his friends who are concerned about his health. Physical examination reveals muscle weakness, dilated pupils, heart rate 140 beats per minute, and blood pressure 180 over 115 mmHg. His friends say he may have taken something orally about two hours ago. Which of the following is the most likely illicit substance? A. Cannabis B. Dextroamphetamine C. Diazepam D. Oxycodone Pause. Answer. **Quick Answer:** **Dextroamphetamine** is the correct option because sympathomimetic stimulants cause marked adrenergic hyperarousal including pupillary dilation, severe hypertension, and tachycardia. **Key Clue:** Dilated pupils, heart rate 140 beats per minute, and blood pressure 180 over 115 mmHg. **Best Answer:** B. Dextroamphetamine **Why It Is Correct:** **Dextroamphetamine** increases synaptic dopamine and norepinephrine, producing acute sympathomimetic toxicity characterized by mydriasis (dilated pupils), extreme hypertension, tachycardia, and muscular agitation. **Why the Other Choices Are Wrong:** * **A:** **Cannabis** intoxication typically presents with conjunctival injection (red eyes), increased appetite, dry mouth, and mild tachycardia, but not severe malignant hypertension or marked pupil dilation. * **C:** **Diazepam** is a benzodiazepine that causes central nervous system depression, ataxia, slurred speech, and respiratory depression rather than sympathetic hyperarousal. * **D:** **Oxycodone** is an opioid agonist that causes **pupillary constriction** (pinpoint pupils), bradycardia, hypotension, and respiratory depression, which is the exact opposite of this patient's presentation. **Test-Taking Pearl:** On board exams, pupil size is the critical pivot point: opioids constrict pupils (miosis), whereas stimulants like **dextroamphetamine** or **cocaine** dilate pupils (mydriasis). Question 2. Dana, a 44-year-old registered nurse, is preparing to be discharged from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help keep her abstinent from alcohol. She has extensive dental work planned to begin within the next month. Which medication would be contraindicated for use given this information? A. Disulfiram B. Naltrexone C. Acamprosate D. Sertraline Pause. Answer. **Quick Answer:** **Naltrexone** is contraindicated because blocking mu-opioid receptors prevents opioid analgesics from working during her upcoming dental procedures. **Key Clue:** Extensive dental work planned within the next month requiring potential opioid analgesia. **Best Answer:** B. Naltrexone **Why It Is Correct:** **Naltrexone** is a mu-opioid receptor antagonist that blocks the euphoric and analgesic effects of opioids. If prescribed to a patient undergoing extensive dental procedures requiring opioid analgesics, **naltrexone** will block pain relief and can precipitate acute opioid withdrawal if opioids are administered. **Why the Other Choices Are Wrong:** * **A:** **Disulfiram** inhibits aldehyde dehydrogenase to cause an aversion reaction with alcohol, but it does not interact with opioid receptors or block dental pain management. * **C:** **Acamprosate** modulates GABA and glutamate neurotransmission to maintain alcohol abstinence and is excreted by the kidneys, making it completely safe for patients requiring opioid analgesics for procedures. * **D:** **Sertraline** is an SSRI antidepressant that does not block opioid analgesia, although it is not a primary FDA-approved craving reduction agent for alcohol abstinence. **Test-Taking Pearl:** Always screen for upcoming surgeries or invasive procedures before initiating **naltrexone** or **Vivitrol**, as opioid blockade prevents standard perioperative pain management. Question 3. Match the substance with the characteristic withdrawal symptoms below: muscle cramps, joint aches (arthralgia), diarrhea, rhinorrhea, lacrimation, and piloerection. A. Amphetamine B. Opioid C. Alcohol D. Cannabis Pause. Answer. **Quick Answer:** **Opioid** withdrawal causes multi-system autonomic rebounding including muscle cramps, joint aches, lacrimation, rhinorrhea, and diarrhea. **Key Clue:** Muscle cramps, joint aches, rhinorrhea, lacrimation, and diarrhea. **Best Answer:** B. Opioid **Why It Is Correct:** **Opioid** withdrawal results from the loss of mu-opioid receptor stimulation, leading to autonomic surge, severe gastrointestinal hypermotility (diarrhea and cramps), flu-like lacrimation and rhinorrhea, and musculoskeletal pain evaluated via the **COWS** scale. **Why the Other Choices Are Wrong:** * **A:** **Amphetamine** withdrawal produces crash symptoms including severe depression, fatigue, vivid dreams, increased appetite, and psychomotor slowing. * **B:** Incorrect choice as this is the correct answer. * **C:** **Alcohol** withdrawal produces central nervous system excitability with hand tremors, sweating, hypertension, tachycardia, confusion, and potential seizures or delirium tremens. * **D:** **Cannabis** withdrawal produces mild restlessness, irritability, insomnia, decreased appetite, and mild abdominal discomfort without severe autonomic collapse. **Test-Taking Pearl:** **COWS** measures opioid withdrawal symptoms, whereas **CIWA-Ar** measures alcohol withdrawal symptoms; memorize which scale applies to which substance. Next Study Step. Review **Fitzgerald Chapter 11 Alcohol Withdrawal Protocols and Pharmacotherapy** to master **CIWA** scoring, benzodiazepine symptom-triggered regimens, and the pharmacology of **acamprosate**, **disulfiram**, and **naltrexone**. * **Why this is the best next step:** It cements the critical exam distinctions between opioid protocols (**COWS** and **naloxone**) and alcohol protocols (**CIWA**, thiamine prior to glucose, and anti-craving agents). * **What knowledge gap it closes:** It eliminates confusion regarding when to select **acamprosate** over **naltrexone** in patients with liver disease versus renal impairment. * **What confusion it helps prevent on boards:** It prevents picking **naloxone** when the question stem is actually asking for alcohol craving reduction or chronic opioid maintenance therapy. Next. Topic. Stimulant Intoxication Signs. Bottom Line Summary. - **Stimulant intoxication** presents with sympathomimetic hyperarousal, including **tachycardia** (heart rate exceeding 100 to 140 beats per minute), severe **hypertension** (systolic blood pressure over 180 mmHg), and **pupillary dilation**. - Central nervous system stimulants tested on boards include **dextroamphetamine**, **amphetamine** salts, **methamphetamine**, **methylphenidate**, and **cocaine**. - Physical signs of acute toxicity include muscle weakness, diaphoresis, chills, nausea, vomiting, chest pain, cardiac arrhythmias, confusion, seizures, and potential sudden cardiac death. - Psychological signs include euphoria, hypervigilance, agitation, grandiosity, impaired judgment, paranoia, and tactile hallucinations such as formication. - Peak physical and autonomic effects after oral ingestion typically manifest within 1 to 2 hours post-ingestion. - **Safety alert**: Severe stimulant toxicity can trigger lethal hypertensive crisis, acute myocardial infarction, aortic dissection, hyperthermia, and status epilepticus. - **Board trap**: Do not confuse **pupillary dilation** seen in stimulant intoxication with the **pupillary constriction** seen in opioid toxicity. - **First-line**: Immediate management prioritizes airway protection, cardiac monitoring, cooling measures for hyperthermia, and **benzodiazepines** to control agitation and hypertension. Clinical Overview of Stimulant Intoxication. Stimulant intoxication occurs following the recent use of central nervous system stimulants such as **dextroamphetamine**, **amphetamine** salts, **methamphetamine**, **methylphenidate**, or **cocaine**. These agents markedly increase synaptic concentrations of dopamine, norepinephrine, and serotonin by stimulating neurotransmitter release and blocking presynaptic reuptake in the mesolimbic circuit and autonomic nervous system. Cardiovascular and autonomic manifestations drive the physical presentation. Synaptic surges of norepinephrine activate peripheral alpha-1 and beta-1 adrenergic receptors, resulting in marked vasoconstriction, severe **hypertension** with blood pressures reaching 180 over 115 mmHg or higher, and pronounced **tachycardia** exceeding 140 beats per minute. Sympathomimetic stimulation of the pupillary dilator muscle produces classic bilateral **pupillary dilation** (mydriasis). Muscle weakness, muscle twitching, or psychomotor agitation often accompany these autonomic shifts. Psychiatric features range from euphoric grandiosity and hypervigilance to severe anxiety, panic, paranoia, and agitation. High doses or prolonged use can precipitate stimulant-induced psychosis with persecutory delusions, auditory hallucinations, and tactile hallucinations such as the sensation of bugs crawling under the skin. Signpost Guidelines and Clinical Pearls. Safety Alert. Severe stimulant intoxication poses immediate life-threatening risks. Autonomic hyperarousal can precipitate acute myocardial infarction, coronary vasospasm, lethal ventricular arrhythmias, stroke, or aortic dissection. Malignant hyperthermia and rhabdomyolysis can lead to acute renal failure. Initial clinical management must immediately establish airway, breathing, and circulation, secure continuous cardiac monitoring, and initiate intravenous **benzodiazepines** such as **lorazepam** or **diazepam** to suppress central sympathetic outflow, reduce blood pressure, and manage psychomotor agitation. Board Trap. A classic board trap is misidentifying the ocular and autonomic findings when distinguishing between drug classes. Stimulant intoxication and opioid withdrawal both cause **pupillary dilation** and **tachycardia**. However, stimulant intoxication is characterized by severe **hypertension**, elevated body temperature, and psychomotor agitation, whereas opioid withdrawal presents with lacrimation, rhinorrhea, piloerection, abdominal cramps, and diarrhea. Conversely, opioid intoxication presents with **pupillary constriction** (miosis), bradycardia, and respiratory depression. First-Line Interventions. For acute stimulant-induced agitation and sympathomimetic hyperarousal, intravenous **benzodiazepines** serve as **first-line** pharmacotherapy. Non-pharmacological supportive care in a quiet, low-stimulation environment should be initiated concurrently. Beta-blockers without alpha-blockade should generally be avoided in acute **cocaine** or **amphetamine** toxicity due to the risk of unopposed alpha-adrenergic stimulation causing worsening hypertension and coronary vasospasm. Sample Practice Question. Question 1. A 19-year-old man is brought to the emergency department by his friends who are concerned about his health. Physical examination reveals muscle weakness, dilated pupils, heart rate 140 beats per minute, and blood pressure 180 over 115 mmHg. His friends say he may have taken something orally about two hours ago. Which of the following is the most likely illicit substance? A) Cannabis B) Dextroamphetamine C) Diazepam D) Oxycodone Pause. Answer: B. Quick Answer. **Dextroamphetamine** is the correct choice because acute stimulant intoxication presents with severe sympathomimetic signs including marked tachycardia, severe hypertension, pupillary dilation, and muscle weakness. Key Clue. The combination of **pupillary dilation**, heart rate 140 beats per minute, blood pressure 180 over 115 mmHg, and onset two hours after oral ingestion drives the diagnosis of stimulant toxicity. Best Answer. B) Dextroamphetamine Why It Is Correct. **Dextroamphetamine** is a central nervous system stimulant that causes excessive synaptic release and reuptake blockade of dopamine and norepinephrine. Oral ingestion reaches peak plasma concentrations in 1 to 2 hours, presenting clinically with severe autonomic hyperarousal, marked **tachycardia**, severe **hypertension**, **pupillary dilation**, and muscle weakness or agitation. Why the Other Choices Are Wrong. - **A**: **Cannabis** intoxication typically produces conjunctival injection, increased appetite, dry mouth, and mild tachycardia, but does not cause severe hypertension of 180 over 115 mmHg, marked pupillary dilation, or muscle weakness. - **C**: **Diazepam** is a central nervous system depressant whose intoxication causes sedation, ataxia, slurred speech, and respiratory depression, rather than autonomic hyperarousal, tachycardia, and hypertension. - **D**: **Oxycodone** is an opioid agonist whose toxicity manifests with **pupillary constriction**, respiratory depression, hypotension, and bradycardia, which is the exact physiological opposite of this clinical presentation. Test-Taking Pearl. When evaluating substance toxicity stems, check pupil size and vital signs first. **Pupillary dilation** paired with **tachycardia** and severe **hypertension** signals stimulant toxicity, whereas **pupillary constriction** paired with respiratory depression signals opioid toxicity. 💡 *Would you like to review stimulant withdrawal management or move on to alcohol and sedative withdrawal protocols next?* Next. New section. Brain Reward System (Table 11-2). Topic. Mesolimbic Dopamine Circuit. Bottom Line Summary. * The **mesolimbic dopamine circuit** connects the **ventral tegmental area** (dopaminergic cell bodies) to the **ventral striatum** (pleasure and reward target). * Natural rewards like food, sex, and social connection trigger baseline dopamine release, whereas drugs of abuse like **cocaine** or **amphetamines** cause exaggerated dopamine surges that alter synaptic communication. * Diagnostic criteria for **substance use disorder** require 2 or more of 11 criteria within a 12-month period, categorized as mild (2 to 3 symptoms), moderate (4 to 5 symptoms), or severe (6 or more symptoms). * Neuroplastic changes in the reward circuitry persist beyond acute detoxification, driving chronic cravings and high relapse risk long after physical withdrawal resolves. * The **amygdala** conditions emotional learning to drug cues, while the **hippocampus** stores specific memories of the drug experience. * Executive choice and impulse control reside in the **medial prefrontal cortex**, **anterior cingulate cortex**, and **orbitofrontal cortex**, which become impaired as addiction progresses. * The **locus coeruleus** supplies norepinephrine for autonomic arousal, while the **dorsal raphe nucleus** supplies serotonin for mood and behavioral activation. High-Yield Concept Map: Mesolimbic Dopamine Circuit (Table 11-2). Anatomical Core of the Reward Pathway. The **mesolimbic dopamine circuit** is the primary neural pathway driving reward, reinforcement, and motivation. It evolved to reinforce behaviors necessary for survival, such as eating food, mating, and engaging in social bonding. * **Ventral tegmental area**: Houses the cell bodies of dopaminergic neurons. It acts as the origin point of the mesolimbic pathway, projecting axons directly to forebrain structures. * **Ventral striatum**: Includes the **nucleus accumbens**, which serves as the primary dopaminergic target of projections from the **ventral tegmental area**. This region acts as the pleasure center, translating dopamine release into the sensation of reward. Memory, Emotion, and Physiologic Integration. The reward circuit relies on surrounding limbic and subcortical structures to link pleasure with memory, affect, and bodily needs. * **Amygdala**: Responsible for conditioned learning and attaching emotional significance to experiences. It pairs drug consumption with environmental cues, generating emotional triggers when exposed to sights or places associated with past use. * **Hippocampus**: Formulates and stores explicit declarative memories of drug experiences. It records the context, environment, and specific details of substance administration. * **Hypothalamus**: Coordinates reward signaling with homeostatic bodily drives, integrating basic physiological needs such as hunger and thirst with reward seeking. Executive Control and Modulatory Neurotransmitter Systems. Upper cortical regions regulate decision making, while subcortical brainstem nuclei modulate arousal and affective states. * **Frontal regions**: Comprising the **medial prefrontal cortex**, **anterior cingulate cortex**, and **orbitofrontal cortex**. These structures oversee executive function, valuation, impulse inhibition, and conscious choice. * **Locus coeruleus**: The principal origin of noradrenergic neurons in the brain. It regulates autonomic arousal, vigilance, and physical activation. * **Dorsal raphe nucleus**: The primary site of serotonergic cell bodies. It modulates mood regulation, impulse control, and emotional activation across the circuit. Pathophysiology of Substance Dysregulation. Drugs of abuse hijack this evolutionary framework by producing massive, artificial surges of synaptic dopamine that far exceed physiological levels produced by natural rewards. * **First-line** clinical understanding: Recognize that chronic substance exposure causes long-term structural and functional remodeling of brain circuits. These neuroadaptations persist long after physical detoxification is complete. * **Safety alert**: Neurological rewiring impairs frontal executive inhibition, rendering patients vulnerable to intense cravings when exposed to environmental cues processed by the **amygdala** and **hippocampus**. * **Board trap**: Assuming that completing acute withdrawal or detoxification restores normal reward circuitry. Cravings and relapse risk remain high because circuit dysregulation persists for months to years. Stacked Contrast: Natural Rewards vs. Drugs of Abuse. Natural Rewards * Stimulus: Food, sex, social connection, music. * Dopamine release: Moderate, physiological, transient surge. * Circuit impact: Preserves normal synaptic signaling and executive control in frontal regions. Drugs of Abuse * Stimulus: **Cocaine**, **amphetamines**, opioids, alcohol. * Dopamine release: Exaggerated, artificial, pathological flood into the **ventral striatum**. * Circuit impact: Alters synaptic communication, downregulates receptors, weakens frontal executive control, and embeds persistent drug memories. Stacked Contrast: Amygdala vs. Hippocampus in Reward. **Amygdala** * Primary function: Attaches emotional feeling and conditioned learning to drug use. * Board clue: Triggered by emotional states or environmental cues that spark sudden cravings. **Hippocampus** * Primary function: Stores factual memory of the drug experience, location, and context. * Board clue: Remembers the specific steps, places, and details surrounding prior substance use. Board Practice Question. Question 1. The region of the brain that is responsible for conditioned learning and connecting an experience with emotion is the: * A. Cerebellum * B. Ventral striatum * C. Hypothalamus * D. Amygdala Pause. Answer. Quick Answer. The **amygdala** is the limbic structure responsible for emotional processing and conditioned learning within the reward system. Key Clue. The phrase "conditioned learning and connecting an experience with emotion" in the stem identifies the emotional memory hub of the brain reward circuit. Best Answer. D. Amygdala Why It Is Correct. The **amygdala** connects environmental experiences with emotional valence and conditioned learning. In substance use disorders, it pairs drug use with emotional triggers and environmental cues, generating conditioned cravings when those cues are encountered. Why the Other Choices Are Wrong. * A. Cerebellum regulates motor coordination, balance, and cognitive timing rather than emotional conditioning. * B. Ventral striatum contains the **nucleus accumbens**, which serves as the primary dopaminergic pleasure target from the **ventral tegmental area**, rather than the emotional conditioning center. * C. Hypothalamus coordinates autonomic and neuroendocrine functions with basic physiologic drives like hunger and thirst, not emotional conditioned learning. Test-Taking Pearl. When an exam stem asks about emotional triggers, conditioned cravings, or fear responses in addiction, select the **amygdala**. When it asks about the primary pleasure center or dopamine target, select the **ventral striatum**. Concept tested. Brain reward system anatomy and **amygdala** function in conditioned learning. Next. Topic. Cognitive and Emotional Control Centers. Bottom Line. * The **mesolimbic dopamine circuit** serves as the primary reward pathway activated by natural rewards such as food, sex, and social connection, but drugs of abuse cause exaggerated dopamine surges that alter synaptic communication [1-3]. * **Medial prefrontal cortex**, **anterior cingulate cortex**, and **orbitofrontal cortex** provide executive control, decision-making, and choice evaluation, which become chronically dysregulated in substance use disorders source 4. * **Amygdala** connects drug experiences with emotional valence and conditioned learning, driving cue-induced cravings source 5. * **Hippocampus** establishes long-term contextual memories of drug experiences that persist after detoxification [4, 6]. * **Hypothalamus** coordinates brain reward signaling with physiological bodily needs source 7. * **Locus coeruleus** serves as the primary source of norepinephrine neurons regulating arousal, while the **dorsal raphe nucleus** supplies serotonin neurons modulating mood and activation source 7. * **Substance use disorder** diagnosis requires 2 or more of 11 DSM-5-TR criteria within a 12-month period, classified as mild (2 to 3 criteria), moderate (4 to 5 criteria), or severe (6 or more criteria) [8, 9]. Cognitive and Emotional Control Centers. Executive Control and Decision-Making. * Frontal cortical structures include the **medial prefrontal cortex**, **anterior cingulate cortex**, and **orbitofrontal cortex** source 4. * These frontal regions govern executive control, goal-directed choices, risk assessment, and behavioral inhibition source 4. * Chronic substance use causes underlying changes in frontal circuitry that persist beyond physical detoxification, especially in severe cases source 6. Emotional Processing and Conditioned Learning. * **Amygdala** connects drug-using experiences with emotional responses and conditioned learning source 5. It attaches emotional weight to environmental triggers and cues source 5. * **Hypothalamus** integrates reward circuitry signaling with physiological bodily needs and endocrine regulation source 7. Neuromodulatory and Arousal Centers. * **Locus coeruleus** contains norepinephrine cell bodies that regulate autonomic arousal, vigilance, and stress responses during intoxication and withdrawal source 7. * **Dorsal raphe nucleus** contains serotonin cell bodies that modulate mood, impulse control, and emotional activation across the reward circuit source 7. Reward and Memory Integration. * **Ventral tegmental area** houses dopaminergic cell bodies that project directly to the **ventral striatum** to signal reward source 5. * **Hippocampus** stores declarative and contextual memories of drug use, reinforcing repetition of rewarding behaviors [4, 5]. Clinical Signposts and Board Strategy. * **Safety alert:** Underlying changes in brain reward circuitry persist beyond physical detoxification source 6. Patients remain at high risk for cue-induced relapse even after years of sobriety when exposed to major life stressors or environmental triggers [6, 10]. * **Board trap:** Do not confuse the role of the amygdala with the hippocampus. The amygdala links experiences to emotional valence and conditioned learning, while the hippocampus stores explicit drug memories [4, 5]. On board exams, conditioned emotional learning points directly to the amygdala source 11. * **First-line:** Combine pharmacotherapy such as **naltrexone** or **acamprosate** for alcohol use disorder with evidence-based psychosocial interventions including **motivational interviewing**, **cognitive behavioral therapy**, and **contingency contracting** to address both neurobiological dysregulation and cognitive-behavioral triggers [12-14]. Sample Board Practice Questions. Question 1. Question: The region of the brain that is responsible for conditioned learning and connecting an experience with emotion is the: * A. Cerebellum * B. Ventral striatum * C. Hypothalamus * D. Amygdala Pause. Answer: D source 11 **Why it is correct:** The **amygdala** is the primary limbic structure responsible for attaching emotional valence to experiences and establishing conditioned learning [5, 11]. In substance use disorders, the amygdala links environmental cues with the emotional memory of drug reward, driving cue-triggered cravings source 5. **Why the other choices are wrong:** * A. **Cerebellum** coordinates motor balance, posture, and cognition, but does not connect experiences with emotional conditioned learning. * B. **Ventral striatum** receives dopaminergic projections from the ventral tegmental area to encode reward prediction, rather than emotional conditioned learning source 5. * C. **Hypothalamus** integrates reward signals with basic physiological needs and autonomic regulation, rather than emotional conditioned learning source 7. **Test-taking pearl:** When a board question asks for the brain region connecting experiences to emotion or conditioned learning, select the **amygdala** source 11. Question 2. Question: Dana, a 44-year-old registered nurse, is preparing to be discharged from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help keep her abstinent from alcohol. She has extensive dental work planned to begin within the next month. Which medication would be contraindicated for use given this information? * A. **Disulfiram** * B. **Naltrexone** * C. **Acamprosate** * D. **Sertraline** Pause. Answer: B source 15 **Why it is correct:** **Naltrexone** is an opioid receptor antagonist that blocks endogenous and exogenous opioids [15, 16]. Because the patient has scheduled dental surgery requiring opioid analgesics, naltrexone is contraindicated as it would block surgical pain relief or precipitate acute opioid withdrawal if opioids are administered [15, 16]. **Why the other choices are wrong:** * A. **Disulfiram** causes an unpleasant aversion reaction when alcohol is consumed, but it does not block opioid receptors and is not contraindicated for upcoming dental surgery [17, 18]. * C. **Acamprosate** modulates GABA and glutamate transmission, is cleared renally, does not interact with opioids, and is safe for patients with upcoming surgeries [18, 19]. * D. **Sertraline** is an SSRI indicated for depressive or anxiety disorders, not an anti-craving agent contraindicated for scheduled surgery source 18. **Test-taking pearl:** Always check for upcoming surgical procedures or acute pain management needs before prescribing **naltrexone**, as opioid blockade will prevent effective pain control [15, 16]. Question 3. Question: Gary, a 54-year-old man with moderate liver disease, has a history of alcohol use disorder but has been abstinent for the past 3.5 years. At this visit, he reports a number of unfortunate events that have happened recently, including the death of a close sibling and loss of employment. As a result, he states that he is having increased urges to drink again. To prevent a possible relapse by Gary, the PMHNP recommends counseling and treatment with: * A. **Acamprosate** * B. **Naloxone** * C. **Clonidine** * D. **Lorazepam** Pause. Answer: A source 20 **Why it is correct:** **Acamprosate** is the preferred pharmacotherapy for maintaining abstinence and reducing alcohol cravings in patients with liver disease because it is metabolized and excreted by the kidneys rather than the liver [19, 20]. **Why the other choices are wrong:** * B. **Naloxone** is an acute opioid reversal agent (Narcan) and is not indicated for alcohol cravings [20, 21]. * C. **Clonidine** is an alpha-2 adrenergic agonist used to manage autonomic withdrawal symptoms, not an anti-craving agent for relapse prevention [20, 22]. * D. **Lorazepam** is a benzodiazepine used for acute alcohol withdrawal detoxification, not long-term maintenance of abstinence [20, 23]. **Test-taking pearl:** Match anti-craving medications to organ clearance: choose **acamprosate** for patients with liver impairment and **naltrexone** for patients with normal liver function needing craving reduction [16, 19, 20]. Next. End of this drive.